Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Nanobiotechnology Systems-Based Veterinary Formulations
share announcement

Nanobiotechnology Systems-Based Veterinary Formulations

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (20 January 2022) | Viewed by 8837

Special Issue Editors

Prof. Dr. Patrícia Severino

E-Mail Website
Guest Editor
Institute for Technology and Research, Tiradentes University, 49010-390 Aracaju, Brazil
Interests: nanotechnology; drug delivery; biomaterial
Special Issues, Collections and Topics in MDPI journals
Dr. Arnobio A. da Silva-Junior

E-Mail Website
Guest Editor
Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal 59072-570, RN, Brazil
Interests: drug delivery systems; nanobiotechnology; pharmaceutical nanotechnology; polymeric devices
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Classius Ferreira Da Silva

E-Mail Website
Guest Editor
Departamento de Engenharia Química, Universidade Federal de São Paulo (UNIFESP), Rua São Nicolau, 210, Diadema CEP 09913-030, São Paulo, Brazil
Interests: biopolymers; wound dressings; cosmetic mask sheets; drug delivery systems; packaging systems
Special Issues, Collections and Topics in MDPI journals
Dr. Raquel De M. Barbosa

E-Mail Website
Guest Editor
Laboratory of Drug Development, Department of Pharmacy, School of Pharmacy, Federal University of Rio Grande do Norte, Av. Gal. Gustavo Cordeiro de Farias, Petrópolis 59010-180, Natal, Brazil
Interests: drug delivery; nanomedicine; wound healing; polymer-based micelles; liposomes; design and control; quality control; design and production of hybrid nanocomposite and nano-systems (lipid and polymeric) for pharmaceutical and cosmetic applications.
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The development of new medicines and devices for animal care increases life quality and promotes specific treatments for different diseases in the veterinary field. However, despite the recent growth of the veterinary pharmaceutical industry, there is still a lack of suitable pharmaceutical forms that favor reducing the number of doses, animal stress, and side effects. The nanobiotechnological innovation employed in the development of veterinary medicines ensures the productivity and safety of animal origin food. In addition, more suitable treatments for domestic and wild animals are made possible with improvement in pharmacological parameters. Nanobiotechnological systems, such as lipid, polymeric or hybrid nanoparticles, used as matrices for drug release, are versatile approaches that aim at better bioavailability and at reducing drug toxicity. Nanotechnological innovations and their challenges will be widely discussed in this Special Issue, focusing on product development stages (production, validation, quality control, preclinical, and clinical studies).

Prof. Dr. Patrícia Severino
Dr. Arnobio A. da Silva-Junior
Dr. Classius Ferreira Da Silva
Dr. Raquel De M. Barbosa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • animal care
  • veterinary medicines
  • drug delivery
  • lipid nanoparticles
  • liposomes
  • lipid nanocapsules
  • nanoemulsions
  • lipid–polymer formulations
  • hybrid systems
  • polimeric nanoparticles
  • in vitro characterization methods
  • in vivo assays

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 618 KiB  
Article
Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock
by Kamil Uney, Duygu Durna Corum, Ertugrul Terzi and Orhan Corum
Pharmaceutics 2021, 13(7), 990; https://doi.org/10.3390/pharmaceutics13070990 - 30 Jun 2021
Cited by 14 | Viewed by 3061
Abstract
The aim of this study was to determine the pharmacokinetics of carprofen following intravenous (IV), intramuscular (IM) and oral routes to rainbow trout (Oncorhynchus mykiss) broodstock at temperatures of 10 ± 1.5 °C. In this study, thirty-six healthy rainbow trout broodstock [...] Read more.
The aim of this study was to determine the pharmacokinetics of carprofen following intravenous (IV), intramuscular (IM) and oral routes to rainbow trout (Oncorhynchus mykiss) broodstock at temperatures of 10 ± 1.5 °C. In this study, thirty-six healthy rainbow trout broodstock (body weight, 1.45 ± 0.30 kg) were used. The plasma concentrations of carprofen were determined using high-performance liquid chromatography and pharmacokinetic parameters were calculated using non-compartmental analysis. Carprofen was measured up to 192 h for IV route and 240 h for IM, and oral routes in plasma. The elimination half-life (t1/2λz) was 30.66, 46.11, and 41.08 h for IV, IM and oral routes, respectively. Carprofen for the IV route showed the total clearance of 0.02 L/h/kg and volume of distribution at steady state of 0.60 L/kg. For IM and oral routes, the peak plasma concentration (Cmax) was 3.96 and 2.52 μg/mL with the time to reach Cmax of 2 and 4 h, respectively. The bioavailability was 121.89% for IM route and 78.66% for oral route. The favorable pharmacokinetic properties such as the good bioavailability and long t1/2λz for IM and oral route of carprofen suggest the possibility of its effective use for the treatment of various conditions in broodstock. Full article
(This article belongs to the Special Issue Nanobiotechnology Systems-Based Veterinary Formulations)
►▼ Show Figures

Graphical abstract

22 pages, 5363 KiB  
Article
Toxoplasma gondii Proteasome Subunit Alpha Type 1 with Chitosan: A Promising Alternative to Traditional Adjuvant
by Zhengqing Yu, Wenxi Ding, Muhammad Tahir Aleem, Junzhi Su, Junlong Liu, Jianxun Luo, Ruofeng Yan, Lixin Xu, Xiaokai Song and Xiangrui Li
Pharmaceutics 2021, 13(5), 752; https://doi.org/10.3390/pharmaceutics13050752 - 19 May 2021
Cited by 4 | Viewed by 2858
Abstract
As an important zoonotic protozoan, Toxoplasma gondii (T. gondii) has spread around the world, leading to infections in one-third of the population. There is still no effective vaccine or medicine against T. gondii, and recombinant antigens entrapped within nanospheres have [...] Read more.
As an important zoonotic protozoan, Toxoplasma gondii (T. gondii) has spread around the world, leading to infections in one-third of the population. There is still no effective vaccine or medicine against T. gondii, and recombinant antigens entrapped within nanospheres have benefits over traditional vaccines. In the present study, we first expressed and purified T. gondii proteasome subunit alpha type 1 (TgPSA1), then encapsulated the recombinant TgPSA1 (rTgPSA1) in chitosan nanospheres (CS nanospheres, rTgPSA1/CS nanospheres) and incomplete Freund’s adjuvant (IFA, rTgPSA1/IFA emulsion). Antigens entrapped in CS nanospheres reached an encapsulation efficiency of 67.39%, and rTgPSA1/CS nanospheres showed a more stable release profile compared to rTgPSA1/IFA emulsion in vitro. In vivo, Th1-biased cellular and humoral immune responses were induced in mice and chickens immunized with rTgPSA1/CS nanospheres and rTgPSA1/IFA emulsion, accompanied by promoted production of antibodies, IFN-γ, IL-4, and IL-17, and modulated production of IL-10. Immunization with rTgPSA1/CS nanospheres and rTgPSA1/IFA emulsion conferred significant protection, with prolonged survival time in mice and significantly decreased parasite burden in chickens. Furthermore, our results also indicate that rTgPSA1/CS nanospheres could be used as a substitute for rTgPSA1/IFA emulsion, with the optimal administration route being intramuscular in mass vaccination. Collectively, the results of this study indicate that rTgPSA1/CS nanospheres represent a promising vaccine to protect animals against acute toxoplasmosis. Full article
(This article belongs to the Special Issue Nanobiotechnology Systems-Based Veterinary Formulations)
►▼ Show Figures

Graphical abstract

14 pages, 2116 KiB  
Article
Evaluation of Bacterial Nanocellulose Membranes Loaded or Not with Nisin as a Complementary Treatment in Surgical Dehorning Wounds in Bovines
by Fábio A. F. Custódio, Leonardo M. de Castro, Erick Unterkircher, Ana Carolina R. C. Porto, Iolanda S. Braga, Alessandre Hataka, Angela F. Jozala and Denise Grotto
Pharmaceutics 2021, 13(5), 688; https://doi.org/10.3390/pharmaceutics13050688 - 11 May 2021
Cited by 5 | Viewed by 2034
Abstract
Treatments of postsurgical dehorning in cattle usually includes topical application of healing agents in wounds. The Bacterial Nanocellulose (BNC) may come to a complementary treatment for these wounds. Two new complementary treatments with BNC and BNC loaded with nisin were evaluated for wound [...] Read more.
Treatments of postsurgical dehorning in cattle usually includes topical application of healing agents in wounds. The Bacterial Nanocellulose (BNC) may come to a complementary treatment for these wounds. Two new complementary treatments with BNC and BNC loaded with nisin were evaluated for wound healing in surgical dehorning in bovine. Hence, two groups of experiments were run, and 12 animals were used in each group. All animals, in right and left horns, received antisepsis treatment. For the first group, the left horn was the control, and on the right one the BNC was applied. For the second group, BNC was applied on the left horn (control) and on the right ones BNC+nisin was applied. In both experiments, wounds were evaluated macroscopically by photographic images and microscopically by histology. For macroscopic evaluations, a significant difference was observed over time, but only in the comparison within the same groups. Microscopic analyzes did not showed significant differences in any type of comparison. In conclusion, there was a clinical improvement in the wound healing response with the application of BNC. However, there was no significant difference between BNC compared to the nisin loaded in BNC. For the first time it was applied a BNC in surgical dehorning wounds in bovines and evaluated the efficacy of treatment in a real animal handling situation. Full article
(This article belongs to the Special Issue Nanobiotechnology Systems-Based Veterinary Formulations)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop